Kallikrein-PAR interactions in skin inflammation
激肽释放酶-PAR 在皮肤炎症中的相互作用
基本信息
- 批准号:10208722
- 负责人:
- 金额:$ 25.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2022-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcanthosisAddressAdverse reactionsAffectAtopic DermatitisAttenuatedAutoimmunityBackcrossingsBiologicalBone MarrowCRISPR/Cas technologyCellsCleaved cellCoculture TechniquesCoupledCutaneousData SetDisease remissionEnvironmentF2R geneFDA approvedGeneticGenetically Engineered MouseHematopoieticHistologicHumanHyperactivityImmuneIn VitroInfiltrationInflammationInterleukin-17KininogenaseKnock-outKnockout MiceLesionMeasuresMediatingMessenger RNAModelingMolecularMolecular GeneticsMusOrgan Culture TechniquesOrgan TransplantationPAR-1 ReceptorPathogenesisPathogenicityPathway interactionsPatientsPeptide HydrolasesPhenotypePopulationPrevalenceProteinase-Activated ReceptorsProteinsPsoriasiform DermatitisPsoriasisPublishingResearchResistanceRho-associated kinaseRoleSerine ProteaseSeveritiesSeverity of illnessSignal PathwaySignal TransductionSkinSmall Interfering RNAT-LymphocyteTestingTherapeuticTimeTranscriptTranslatingTumor-infiltrating immune cellsWorkXenograft ModelXenograft procedurechronic inflammatory diseasecytokineexperimental studyimprovedin vivoinhibitor/antagonistinnovationinterleukin-23mouse modelnew therapeutic targetnoveloverexpressionpreventreceptorrecombinase-mediated cassette exchangereduce symptomsskin lesionsmall moleculetherapeutic developmenttherapeutically effectivetranscriptome sequencingwhole genome
项目摘要
Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease hypothesized to promote inflammation
and autoimmunity via cleavage of protease-activated receptors (PAR)1 and PAR2. KLK6 is expressed in skin,
however its biological activities in vivo remain largely unknown. Recent work published by our lab identified
increases in KLK6 mRNA and protein in psoriasis patient lesional skin and primary KCs that decrease rapidly
with treatment and correspond with disease severity. Despite KLK6 being a highly regulated cutaneous
transcript/protein, the pathogenic significance of KLK6 in psoriasis remains unknown.
To address this question, we genetically engineered mice to overexpress KLK6 in KCs (modeling lesional
psoriasis skin). KLK6+ mice spontaneously develop a psoriasiform skin phenotype at the histological, cellular
and molecular levels and RNAseq analyses of KLK6+ mouse skin revealed high correspondence with human
psoriasis and identified significant increases in T cell derived-cytokines Il22 and Il17a/f. To identify the
mechanisms mediating KLK6-elicited inflammation, KLK6+ mice were backcrossed with either PAR1- or
PAR2-deficient (KO) mice. KLK6+PAR2KO mice develop similar levels of skin inflammation as KLK6+ mice. In
contrast, KLK6+PAR1KO mice have attenuated skin inflammation demonstrating a critical pathogenic role for
PAR1, and not PAR2 in KLK6-induced skin inflammation. PAR1 is found on KCs and T cells and signals
through Rac1 and Rho associated kinase (ROCK)2. Using this innovative new mouse model, combined with
genetic knockout approaches, cre-lox technologies and small molecule inhibition targeting strategies coupled
with in vitro co-culture, CRISPR-Cas9 and cell signaling approaches, we will test the hypothesis that KLK6
cleaves PAR1 on KCs and T cells and activates Rac1 and ROCK2, initiating a self-sustaining proinflammatory
loop between KCs and T cells that results in a psoriasis-like proinflammatory environment. Ultimately, we will
show using human psoriasis skin organ cultures and xenograft models that interfering with new targets in this
pathway will improve human psoriasis.
The work proposed herein will identify the cellular mechanism(s) underlying KLK6-PAR1-mediated
inflammation. Successful completion of our aims will identify KLK6 as a critical protease for psoriasis
pathogenesis and KLK6-PAR1 signaling as a new target for therapy. This pathway is profoundly different than
currently targeted cytokine pathways being investigated for the treatment of chronic inflammatory disease and
offers a new direction in psoriasis research and autoimmunity research as a whole.
激肽释放酶相关肽酶6(KLK 6)是一种分泌型丝氨酸蛋白酶,被推测促进炎症
以及通过蛋白酶激活受体(PAR)1和PAR 2的裂解的自身免疫。KLK 6在皮肤中表达,
然而,其体内生物学活性仍然很大程度上未知。我们实验室最近发表的工作确定了
银屑病患者皮损皮肤和原发性KC中KLK 6 mRNA和蛋白的增加,
与治疗和疾病的严重程度相对应。尽管KLK 6是一种高度调节的皮肤
尽管KLK 6在银屑病中的转录/蛋白质的表达水平很低,但KLK 6在银屑病中的致病意义仍然未知。
为了解决这个问题,我们对小鼠进行了基因工程改造,使其在KC中过表达KLK 6(模拟病变)。
牛皮癣皮肤)。KLK 6+小鼠在组织学、细胞学上自发出现银屑病样皮肤表型
KLK 6+小鼠皮肤的分子水平和RNAseq分析显示与人类皮肤的高度对应性。
银屑病,并确定了T细胞衍生的细胞因子IL 22和IL 17 a/f的显著增加。识别
由于介导KLK 6引起的炎症的机制,将KLK 6+小鼠与PAR 1-或
PAR 2缺陷(KO)小鼠。KLK 6 + PAR 2KO小鼠与KLK 6+小鼠发生相似水平的皮肤炎症。在
相比之下,KLK 6 + PAR 1 KO小鼠的皮肤炎症减弱,证明了KLK 6 + PAR 1 KO的关键致病作用。
PAR 1,而不是PAR 2在KLK 6诱导的皮肤炎症中。PAR 1存在于KC和T细胞上,
通过Rac 1和Rho相关激酶(ROCK)2。使用这种创新的新小鼠模型,结合
基因敲除方法、cre-lox技术和小分子抑制靶向策略耦合
通过体外共培养,CRISPR-Cas9和细胞信号传导方法,我们将测试KLK 6
切割KC和T细胞上的PAR 1,并激活Rac 1和ROCK 2,启动自我维持的促炎反应。
KCs和T细胞之间的环,导致银屑病样促炎环境。最终,我们将
显示使用人类银屑病皮肤器官培养物和异种移植物模型,
pathway途径将改善人类牛皮癣。
本文提出的工作将确定KLK 6-PAR 1介导的细胞内机制。
炎症成功完成我们的目标将确定KLK 6作为银屑病的关键蛋白酶
发病机制和KLK 6-PAR 1信号传导作为治疗的新靶点。这条道路与
目前正在研究用于治疗慢性炎性疾病的靶向细胞因子途径,
为银屑病研究和自身免疫研究提供了一个新的方向。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicole Leanne Ward其他文献
Nicole Leanne Ward的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nicole Leanne Ward', 18)}}的其他基金
Kallikrein-PAR interactions in skin inflammation
激肽释放酶-PAR 在皮肤炎症中的相互作用
- 批准号:
10615327 - 财政年份:2018
- 资助金额:
$ 25.54万 - 项目类别:
Kallikrein-PAR interactions in skin inflammation
激肽释放酶-PAR 在皮肤炎症中的相互作用
- 批准号:
10449979 - 财政年份:2018
- 资助金额:
$ 25.54万 - 项目类别:
Project 1: Host Immune Response to Chronic Psoriasis Inflammation
项目 1:宿主对慢性银屑病炎症的免疫反应
- 批准号:
10259876 - 财政年份:2017
- 资助金额:
$ 25.54万 - 项目类别:
Project 1: Host Immune Response to Chronic Psoriasis Inflammation
项目 1:宿主对慢性银屑病炎症的免疫反应
- 批准号:
10005125 - 财政年份:2017
- 资助金额:
$ 25.54万 - 项目类别:
Neurogenic inflammation and psoriasiform dermatitis
神经源性炎症和牛皮癣样皮炎
- 批准号:
8706044 - 财政年份:2013
- 资助金额:
$ 25.54万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 25.54万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 25.54万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 25.54万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 25.54万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 25.54万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 25.54万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 25.54万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 25.54万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 25.54万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 25.54万 - 项目类别:
Research Grant














{{item.name}}会员




